Event

Senate hearing on Valeant, April 2016

Hearing of the Senate Special Committee on Aging on Valeant's price rises on four old drugs.

3 links, 3 backed by primary records

Connections 3

Valeant Pharmaceuticals its chief executive testified Primary record 1
U.S. Senate Special Committee on Aging held the hearing; its chair gave these figures Primary record 1
Philidor Rx Services named in the opening statement of the committee's ranking member, Senator Claire McCaskill Primary record 1

Timeline 1 date

Proof 1 source

Valeant Pharmaceuticals' Business Model: The Repercussions for Patients and the Health Care System, hearing, S. Hrg. 114-846, U.S. Senate Special Committee on Aging, 27 Apr 2016. Primary record
In hindsight, I regret pursuing transactions where the central premise was based on an increase in price, for example, our acquisition of Nitropress and Isuprel from Marathon.
The price increases for the other three drugs were even worse: 720 percent for Isuprel, almost 3,200 percent for Syprine, and nearly 6,000 percent for Cuprimine.
currently there are more questions than answers regarding Valeant's relationship with Philidor, the pharmacy that was managing a key patient assistance program for Valeant.

Page history 1 change